Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Cardiff Oncology (Nasdaq: CRDF) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference in a virtual format on February 25-26, 2026.

Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference in a virtual format on February 25-26, 2026.

Interim CEO Mani Mohindru, PhD will present on 02/25/2026 at 1:20 PM ET. Management will hold 1x1 investor meetings. According to the company, a live webcast and replay will be available via the Events section of the Cardiff Oncology website.

Argus Feb 19 session

+4.49% close to close Open Argus

Details

News Market Reaction – CRDF

In the Feb 19 session, CRDF gained 4.49%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Cardiff Oncology’s continued investor outreach as it moves toward late-...

Analysis

This announcement highlights Cardiff Oncology’s continued investor outreach as it moves toward late-stage development, with management presenting at the Oppenheimer conference on February 25, 2026. Recent history includes strong Phase 2 data in mCRC and leadership changes on Jan 27, 2026, as well as earlier conference appearances. Investors may watch how messaging around clinical progress, cash of $60.6M, and ongoing losses of $11.3M in Q3 2025 shapes sentiment over time.

Key Figures

Royalty revenue: $0.12M Net loss: $11.3M Net loss per share: $0.17 +5 more

Royalty revenue

$0.12M

Q3 2025 results

Net loss

$11.3M

Q3 2025 results

Net loss per share

$0.17

Q3 2025 basic and diluted

R&D expense

$8.2M

Q3 2025 (down year over year)

SG&A expense

$3.9M

Q3 2025 (up year over year)

Cash & investments

$60.6M

As of September 30, 2025

Net cash used

$32.0M

Operating activities, first nine months 2025

Shares outstanding

67,360,564

As of October 30, 2025

Historical Context

5 past events · Latest: Jan 27

5 events

1. Jan 27

   Phase 2 update

   24h Move

   -32.0%

   Positive Phase 2 mCRC data with improved ORR and PFS vs standard of care.

2. Jan 27

   Leadership changes

   24h Move

   -32.0%

   CEO and CFO departures with interim CEO appointed during transition to late stage.

3. Dec 08

   Clinical poster data

   24h Move

   +10.9%

   Phase 1 CMML trial showed tolerability and preliminary efficacy in about 40% of patients.

4. Dec 08

   Investor conference

   24h Move

   +10.9%

   Sidoti virtual conference presentation with webcast and 1x1 investor meetings.

5. Nov 24

   Investor conference

   24h Move

   +2.5%

   Piper Sandler healthcare conference fireside chat and investor meetings.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

plk1 inhibition

1 terms

plk1 inhibition medical

"a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies"

PLK1 inhibition means blocking the activity of the enzyme Polo‑like kinase 1, a protein that helps cells divide. For investors, it signals a drug approach aimed at slowing or stopping fast‑growing tumors by disrupting the cell’s “division machinery,” but it also raises safety and trial‑success questions because the same process is important in healthy tissues; clinical results and side‑effect profiles drive the investment impact.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25-26, 2026.

Details of the presentation can be found below.

Presenter: Mani Mohindru, PhD (Interim CEO) 
Date: 02/25/2026
Time: 1:20 PM ET

Interested parties can register for and access the live webcast for the conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Investor Contact:
Candice Masse
Astr Partners
candice.masse@astrpartners.com 

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Cardiff Oncology (CRDF) present at the Oppenheimer conference in February 2026?

Cardiff Oncology will present on February 25, 2026 at 1:20 PM ET. According to the company, the presentation is part of the Oppenheimer 36th Annual Healthcare Life Sciences Conference held virtually February 25-26, 2026 and includes 1x1 investor meetings.

Who is presenting for Cardiff Oncology (CRDF) at the Oppenheimer 36th Annual Healthcare Life Sciences Conference?

Mani Mohindru, PhD, Interim CEO is the presenter for Cardiff Oncology. According to the company, he will deliver the presentation and management will participate in scheduled 1x1 investor meetings during the virtual conference.

How can investors watch Cardiff Oncology's (CRDF) Oppenheimer conference presentation?

Investors can access a live webcast and a replay via the Cardiff Oncology website Events section. According to the company, registration is available on the Events page for live viewing and the replay after the presentation.

Will Cardiff Oncology (CRDF) hold investor meetings at the Oppenheimer conference?

Yes, management will participate in 1x1 investor meetings during the virtual conference on February 25-26, 2026. According to the company, these meetings accompany the scheduled presentation by the interim CEO on February 25.

What topics will Cardiff Oncology (CRDF) likely cover in the Oppenheimer presentation on February 25, 2026?

The presentation will discuss Cardiff Oncology's clinical-stage programs leveraging PLK1 inhibition across cancer indications. According to the company, management will highlight development progress and engage with investors during the session and 1x1 meetings.